SecBot SecBot
144 ·Filed Apr 1, 2026

KYMR

Kymera Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001950047-26-003151
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine 10b5-1 plan sale by an officer, not a new discretionary decision. Traders should not interpret this as negative sentiment, but rather as part of a pre-established exit strategy. Monitor for completion of the sale via Form 4 filings.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$85.40
T+0 close · Apr 1, 2026 · via day close
Latest settled
+34.27%
T+60 · $114.67
Vs SPY
+20.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 2 $85.40entry
  2. T+1 · 8mo ago −0.15%α −0.63% · $85.27
  3. T+5 · 7mo ago −0.41%α −4.03% · $85.05
  4. T+20 · 7mo ago −5.07%α −14.95% · $81.07
  5. T+60 · 5mo ago +34.27%α +20.11% · $114.67
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to report the proposed sale of 14,640 shares, following a series of recent 10b5-1 plan sales totaling over $12.1M in the past month. This filing is part of an ongoing, pre-arranged selling plan and not an isolated event.

Key Facts

  • Jeremy Chadwick, an officer of Kymera Therapeutics, filed Form 144 to propose the sale of 14,640 common shares.
  • The sale is part of a 10b5-1 trading plan, with recent sales already executed: 7,600 shares (~$649K) on 03/31/2026, 24,727 shares (~$1.98M) on 03/25/2026, 91,250 shares (~$7.06M) on 03/23/2026, and others totaling over $12.1M in the past month.
  • The proposed sale proceeds will be received in cash and are not tied to any new insider decision, as 10b5-1 plans are pre-scheduled.
  • Recent insider activity shows 4 sell transactions in the last 30 days totaling $3.8M, consistent with this pattern.

Financial Impact

Approximately $1.22M based on 14,640 shares at ~$83.29/share (implied from prior sales), a small fraction of Kymera's $6.8B market cap.

insider ownershipshare float

Risk Factors

  • Perception risk: Large cumulative insider sales may be viewed negatively by the market despite being pre-planned.
  • Execution risk: If future sales under this plan accelerate or expand, it could increase selling pressure.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-003151
Document: 0001950047-26-003151-index.html0001950047-26-003151
Document: 0001950047-26-003151.txt0001950047-26-003151

Track record

37 reports on KYMR

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
  2. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  3. Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
  4. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
  5. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
  9. Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 8h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026